Literature DB >> 15896103

On pharmacogenomics and cost-effectiveness analysis at the individual level.

Mohan V Bala, Gary A Zarkin.   

Abstract

Mesh：

Year:  2005        PMID： 15896103     DOI： 10.2165/00019053-200523050-00011

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  A note on the estimation of the equity-efficiency trade-off for QALYs.

Authors:  M Johannesson; U Gerdtham
Journal:  J Health Econ       Date:  1996-06       Impact factor: 3.883

3.  Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

Authors:  Adam La Caze
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Cost-effectiveness analysis in a setting of budget constraints--is it equitable?

Authors:  P A Ubel; M L DeKay; J Baron; D A Asch
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245
  4 in total
  2 in total

1.  Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.

Authors:  Mohan V Bala; Josephine A Mauskopf
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.